Edition:
United States

Cesca Therapeutics Inc (KOOL.OQ)

KOOL.OQ on NASDAQ Stock Exchange Capital Market

0.28USD
17 Aug 2018
Change (% chg)

$0.00 (+1.26%)
Prev Close
$0.28
Open
$0.28
Day's High
$0.28
Day's Low
$0.27
Volume
16,064
Avg. Vol
103,315
52-wk High
$6.43
52-wk Low
$0.26

Select another date:

Wed, May 16 2018

BRIEF-Cesca Prices $5.5 Million Public Offering

* CESCA THERAPEUTICS INC - IS OFFERING UNITS AT A PRICE OF $0.60 PER UNIT.

BRIEF-Cesca Therapeutics Reports Q1 Loss Per Share $0.27

* CESCA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Cesca Therapeutics Says Offering Up To 3.2 Million Units

* CESCA THERAPEUTICS SAYS OFFERING UP TO 3.2 MILLION UNITS, EACH UNIT CONSISTING OF 1 SHARE OF COMMON STOCK, ONE COMMON WARRANT TO PURCHASE 1 SHARE OF STOCK Source text: (https://bit.ly/2I8M01T) Further company coverage:

BRIEF-Cesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina For X-Series Products

* CESCA THERAPEUTICS ANNOUNCES EVALUATION AGREEMENT WITH THE UNIVERSITY OF NORTH CAROLINA LINEBERGER ADVANCED CELLULAR THERAPEUTICS FACILITY FOR X-SERIES™ PRODUCTS THAT PROVIDE AUTOMATED, CLOSED SYSTEM CELLULAR PROCESSING

BRIEF-Cesca Therapeutics Entered Amendment To Revolving Line Of Credit Facility

* CESCA THERAPEUTICS SAYS ON APRIL 16, ENTERED AMENDMENT TO ITS REVOLVING LINE OF CREDIT FACILITY - SEC FILING

BRIEF-Cesca Therapeutics Announces First Evaluation Agreement With A Leading U.S. Academic Research Institution For X-Series Products

* CESCA THERAPEUTICS ANNOUNCES FIRST EVALUATION AGREEMENT WITH A LEADING U.S. ACADEMIC RESEARCH INSTITUTION FOR X-SERIES™ PRODUCTS THAT PROVIDE AUTOMATED, CLOSED SYSTEM CELLULAR PROCESSING

BRIEF-Cesca Therapeutics Announces Registered Direct Offering

* CESCA THERAPEUTICS INC - ‍PURCHASE AGREEMENTS WITH CERTAIN INSTITUTIONAL INVESTORS TO 609,636 SHARES OF STOCK AT A PURCHASE PRICE OF $2.27 PER SHARE​ Source text for Eikon: Further company coverage:

BRIEF-Cesca Subsidiary Expands Into CAR-T Related Contract Development And Manufacturing

* CESCA’S DEVICE SUBSIDIARY, THERMOGENESIS, EXPANDS INTO CAR-T RELATED CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) SERVICES

Select another date: